He emphasized the cumulative milestone of 64,000 implants sold globally. Management expressed optimism for FDA approval of CGuard Prime in Q3 2025 and is actively addressing feedback.

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received ...